{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T09:56:36Z","timestamp":1649152596266},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mod Rheumatol"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1007\/s10165-010-0320-8","type":"journal-article","created":{"date-parts":[[2010,6,15]],"date-time":"2010-06-15T10:24:25Z","timestamp":1276597465000},"page":"561-565","source":"Crossref","is-referenced-by-count":2,"title":["Etanercept response in patients with rheumatoid arthritis after secondary loss of efficacy of infliximab"],"prefix":"10.1093","volume":"20","author":[{"given":"Hiroaki","family":"Matsuno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2010,6,16]]},"reference":[{"key":"320_CR1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0002-9343(99)80109-0","volume":"99","author":"DA Fox","year":"1995","unstructured":"Fox DA. Biological therapies: a novel approach to the treatment of autoimmune disease. Am J Med. 1995;99:82\u20138.","journal-title":"Am J Med"},{"key":"320_CR2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","volume":"14","author":"M Feldmann","year":"1996","unstructured":"Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14:397\u2013440.","journal-title":"Annu Rev Immunol"},{"key":"320_CR3","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.1780361206","volume":"36","author":"MJ Elliott","year":"1993","unstructured":"Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alfa. Arthritis Rheum. 1993;36:1681\u201390.","journal-title":"Arthritis Rheum"},{"issue":"9602","key":"320_CR4","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","volume":"370","author":"JS Smolen","year":"2007","unstructured":"Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370(9602):1861\u201374.","journal-title":"Lancet"},{"key":"320_CR5","first-page":"548","volume":"39","author":"H Matsuno","year":"2008","unstructured":"Matsuno H. Expensive medical expense and cost-reduction strategies in patients with rheumatoid arthritis. Clin Rheumatol Related Res. 2008;39:548\u201354. (in Japanese; abstract in English).","journal-title":"Clin Rheumatol Related Res"},{"key":"320_CR6","first-page":"2398","volume":"33","author":"G Gartlehner","year":"2006","unstructured":"Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and meta-analysis. J Rheumatol. 2006;33:2398\u2013408.","journal-title":"J Rheumatol"},{"key":"320_CR7","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(89)92442-2","volume":"1","author":"DM Heijde Van der","year":"1989","unstructured":"Van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB. Effect of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989;1:1036\u20138.","journal-title":"Lancet"},{"key":"320_CR8","first-page":"585","volume":"16","author":"HA Fuchs","year":"1989","unstructured":"Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2\u00a0years of disease. J Rheumatol. 1989;16:585\u201391.","journal-title":"J Rheumatol"},{"key":"320_CR9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/art.10092","volume":"46","author":"JR O\u2019Dell","year":"2002","unstructured":"O\u2019Dell JR. Treating rheumatoid arthritis; a window of opportunity? Arthritis Rheum. 2002;46:283\u20135.","journal-title":"Arthritis Rheum"},{"key":"320_CR10","doi-asserted-by":"crossref","unstructured":"American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum. 2002; 46:328\u201346.","DOI":"10.1002\/art.10148"},{"issue":"9194","key":"320_CR11","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Inflixamab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354(9194):1932\u20139.","journal-title":"Lancet"},{"key":"320_CR12","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","volume":"130","author":"LW Moreland","year":"1999","unstructured":"Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999;130:478\u201386.","journal-title":"Ann Intern Med"},{"key":"320_CR13","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/art.21655","volume":"54","author":"D Heijde van der","year":"2006","unstructured":"van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum. 2006;54:1063\u201374.","journal-title":"Arthritis Rheum"},{"key":"320_CR14","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/art.21519","volume":"54","author":"FC Breedveld","year":"2006","unstructured":"Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicentre, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26.","journal-title":"Arthritis Rheum"},{"key":"320_CR15","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/ard.2003.009563","volume":"62","author":"LB Putte van de","year":"2003","unstructured":"van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PL, et al. Efficacy and safety of the fully human anti-tumor necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12\u00a0week, phase II study. Ann Rheum Dis. 2003;62:1168\u201377.","journal-title":"Ann Rheum Dis"},{"key":"320_CR16","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","volume":"8","author":"JJ Gomez-Reino","year":"2006","unstructured":"Gomez-Reino JJ, Carmona L, BIOBADASER group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther. 2006;8:R29.","journal-title":"Arthritis Res Ther"},{"key":"320_CR17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","volume":"56","author":"KI Hyrich","year":"2007","unstructured":"Hyrich KI, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum. 2007;56:13\u201320.","journal-title":"Arthritis Rheum"},{"key":"320_CR18","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/ard.2006.068304","volume":"66","author":"DE Furst","year":"2007","unstructured":"Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis. 2007;66:893\u20139.","journal-title":"Ann Rheum Dis"},{"key":"320_CR19","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jbspin.2006.03.010","volume":"74","author":"JM Berthelot","year":"2007","unstructured":"Berthelot JM, Varin S, Cormier G, Tortellier L, Guillot P, Glemarec J, et al. 25\u00a0mg etanercept once weekly in rheumatoid arthritis and spondylarthropathy. Joint Bone Spine. 2007;74:144\u20137.","journal-title":"Joint Bone Spine"},{"key":"320_CR20","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","volume":"370","author":"JS Smolen","year":"2007","unstructured":"Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370:1861\u201374.","journal-title":"Lancet"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10165-010-0320-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T16:27:28Z","timestamp":1646843248000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10165-010-0320-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,16]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["320"],"URL":"https:\/\/doi.org\/10.1007\/s10165-010-0320-8","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,16]]}}}